Bernardino Clavo, \u00c1ngeles C\u00e1novas-Molina, Mario Federico, Gregorio Mart\u00ednez-S\u00e1nchez, Gretel Ben\u00edtez, Saray Galv\u00e1n, Yolanda Ramallo-Fari\u00f1a, Himar Fabelo, Sara Cazorla-Rivero, Elba Lago-Moreno, Carla Antonilli, Juan A. D\u00edaz-Garrido, Ignacio J. Jorge, Gustavo Marrero-Callico, Delvys Rodr\u00edguez-Abreu, Francisco Rodr\u00edguez Esparrag\u00f3n.<\/p>\n
SIMPLE SUMARY<\/strong><\/p>\n Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of chemotherapy. CIPN can lead to a dose reduction and\/or the interruption of chemotherapy, limiting its effectiveness, while chronic CIPN decreases patients\u2019 quality of life. Unfortunately, the only evidence-based treatment for CIPN-related pain, duloxetine, provides only a modest clinical benefit, and there is no effective clinical management option for numbness and tingling. This narrative review summarizes the mechanisms underlying CIPN and the effects of ozone. It also summarizes experimental studies (18) and clinical reports (27) published between 1995 and 2025 that offer preliminary evidence supporting the potential role of ozone treatment in managing CIPN and highlight the need for ongoing randomized clinical trials to establish its efficacy.<\/p>\n ABSTRACT<\/strong><\/p>\n Background: <\/strong><\/p>\n Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of chemotherapy. CIPN can lead to a dose reduction and\/or the interruption of chemotherapy, limiting its effectiveness, while chronic CIPN decreases patients\u2019 quality of life. Improvements in cancer treatment and patients\u2019 survival have increased the number of patients living with CIPN. The only evidence-based treatment for CIPN-related pain, duloxetine, provides only modest clinical benefit, and there is no effective clinical management option for numbness and tingling. Several experimental studies and clinical reports suggest that adjuvant ozone treatment may be beneficial in managing CIPN.<\/p>\n